ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11161)・商品コード:DATA904C11161
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:47
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine -based warheads to selectively kill cancer cells. It conducts research on next-generation cancer biologic therapies. ADCT targets a wide range of cancers such as breast lung, prostate, renal, blood cancer, and others. The company has exclusive technology license partnership with Spirogen for the development of PBD-based Antibody-Drug-Conjugates. It also has corporate partnerships with MedImmune, Cancer Research Technology, Genmab, and others. ADCT is headquartered in Lausanne, Switzerland.

ADC Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
Private Equity 14
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
Partnerships 15
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
Licensing Agreements 20
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
Equity Offering 29
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA – Key Competitors 32
ADC Therapeutics SA – Key Employees 33
ADC Therapeutics SA – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Product Approvals 35
Jun 09, 2017: ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 35
Clinical Trials 36
Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences 36
Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting 37
Apr 11, 2018: ADC Therapeutics to Present on its Lymphoid Malignancies Drug Candidate DCT-301 at the American Association for Cancer Research (AACR) Annual Meeting 38
Dec 11, 2017: ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301 39
Dec 11, 2017: ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402 41
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data for ADCT-402 at American Society of Hematology 2017 Annual Meeting 43
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data on ADCT-301 at the American Society of Hematology 2017 Annual Meeting 44
Jun 16, 2017: ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma 45
Jun 16, 2017: ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA, Key Competitors 32
ADC Therapeutics SA, Key Employees 33
ADC Therapeutics SA, Other Locations 34

List of Figures
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11161)販売に関する免責事項を必ずご確認ください。
★調査レポート[ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆